HOUSE BILL REPORT
HB 1850
This analysis was prepared by non-partisan legislative staff for the use of legislative members in
their deliberations. This analysis is not a part of the legislation nor does it constitute a
statement of legislative intent.
As Reported by House Committee On:
Health Care & Wellness
Title: An act relating to prescription information.
Brief Description: Limiting the sale or use of prescription information.
Sponsors: Representatives Pedersen, Schual-Berke, Morrell, Cody, Hasegawa, Moeller, Rolfes, Lantz, Green, Hurst, Campbell and Ormsby.
Brief History:
Health Care & Wellness: 2/19/07, 2/22/07 [DP].
Brief Summary of Bill |
|
HOUSE COMMITTEE ON HEALTH CARE & WELLNESS
Majority Report: Do pass. Signed by 9 members: Representatives Cody, Chair; Morrell, Vice Chair; Barlow, Campbell, Green, Moeller, Pedersen, Schual-Berke and Seaquist.
Minority Report: Without recommendation. Signed by 3 members: Representatives Hinkle, Ranking Minority Member; Alexander, Assistant Ranking Minority Member and Condotta.
Staff: Dave Knutson (786-7146).
Background:
Health care information companies purchase electronic records of prescriptions from
pharmacies and other sources and link them with information about doctors that is licensed
from the Physician Masterfile of the American Medical Association (AMA). The Physician
Masterfile contains information on virtually every physician in the United States, including
physicians who do not belong to the AMA. This information can then be sold to
pharmaceutical companies who may use it to target individual physicians using their personal
prescribing patterns. In 2005, the AMA received $44.5 million from sales of physician
prescription information from the Masterfile. The AMA recently began a prescribing data
restriction program which allows physicians to prevent their own prescribing data from being
released to pharmaceutical companies through an opt-out process.
Summary of Bill:
The sale or use of prescription information containing patient or prescriber identifiable
information by pharmacy benefits managers, insurance companies, electronic transmission
intermediary, retail, mail order or internet pharmacy, or other similar entity for any
commercial purpose is prohibited. Commercial purposes include: advertising, marketing,
promotion, and any activities that can influence the sales or market share of a pharmaceutical
product, the prescribing behavior of an individual prescriber, or evaluate the effectiveness of
a pharmaceutical detailing sales force. A violation of this act will be considered a violation
of chapter 19.86 RCW, the Consumer Protection Act.
Appropriation: None.
Fiscal Note: Not requested.
Effective Date: The bill takes effect 90 days after adjournment of session in which bill is passed.
Staff Summary of Public Testimony:
(In support) Most physicians are not aware that their prescribing information is collected or
sold by the American Medical Association (AMA). The AMA opt-out provision is not well-known by physicians. Physicians' prescribing information should not be sold to
pharmaceutical companies to pressure physicians to change their prescribing practices.
(Opposed) The sale and use of physicians' prescribing information can help with drug recalls,
dear doctor letters, and other valuable purposes.
Persons Testifying: (In support) Representative Pedersen, prime sponsor; Steve Albrecht,
Washington Academy of Family Physicians; Dr. Art Zoloth; and Lauren Moughon, American
Association of Retired Persons, Washington.
(Opposed) Cliff Webster, Pharmaceutical Research and Manufacturers of America.